CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia

Am J Hematol. 2003 Jul;73(3):149-53. doi: 10.1002/ajh.10337.

Abstract

This study investigated the clinical characteristics and prognostic relevance of CD34 expression in 47 patients with acute promyelocytic leukemia (APL), showing t(15;17) or PML/RARalpha. Ten (21.3%) of the APL patients were CD34(+). CD34 expression was associated with hypogranular morphology (P = 0.002) and hyperleukocytosis (P = 0.015). However, there were no statistically significant differences in age, sex, hemoglobin level, platelet count, or percentage of blasts between the CD34(+) and CD34(-) APL groups. Multiplex RT-PCR analysis showed that the L-form (BCR1) and S-form (BCR3) were correlated with CD34(-) APL and CD34(+) APL, respectively. Despite the lack of a difference in the complete remission rate, overall survival (OS) and disease-free survival (DFS) were significantly lower in the CD34(+) group than in the CD34(-) group (P = 0.012 and P = 0.0051, respectively). By multivariate analysis, the CD34(+) group showed a significant independent variable in DFS compared with the CD34(-) group, but this was not demonstrated for OS. In conclusion, CD34 expression in APL is a unique clinical feature associated with leukocytosis and atypical morphology with hypogranular pattern and is associated with a poor clinical outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antigens, CD / blood*
  • Antigens, CD34 / blood*
  • Biomarkers / blood
  • Blood Cell Count
  • Chromosomes, Human, Pair 15
  • Chromosomes, Human, Pair 17
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Promyelocytic, Acute / blood*
  • Leukemia, Promyelocytic, Acute / genetics
  • Leukemia, Promyelocytic, Acute / immunology
  • Leukemia, Promyelocytic, Acute / mortality
  • Male
  • Middle Aged
  • Prognosis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Rate
  • Time Factors
  • Translocation, Genetic
  • Treatment Outcome

Substances

  • Antigens, CD
  • Antigens, CD34
  • Biomarkers